论文部分内容阅读
目的探讨在端粒酶峰值时相与谷值时相施以端粒酶抑制剂治疗肝癌裸鼠移植瘤的疗效差异。方法24只BALB/C裸鼠进行为期4wk的LD12∶12节律同步化。移植肝癌细胞(SMMC-7721)于裸鼠以建立肝癌裸鼠移植瘤。在移植后2wk,瘤体内注射端粒酶抑制剂hTERT-5’RZ以治疗肝癌裸鼠移植瘤,注射时间点为9HALO或21HALO,持续2wk。结果21HALO治疗组的肿瘤抑制率(65%)和端粒酶抑制率(90%)高于9HALO治疗组的肿瘤抑制率(48%)和端粒酶抑制率(70%),差异具有统计学意义。结论在肿瘤DNA合成期注射以端粒酶为作用靶点的核酶能更好地抑制肝癌生长,具有更好的治疗效果。
Objective To investigate the therapeutic effect of telomerase inhibitor on transplanted hepatocellular carcinoma in nude mice with telomerase peak phase and trough phase. Methods Twenty-four BALB / C nude mice were subjected to 4wk LD12:12 rhythm synchronization. Liver cancer cells (SMMC-7721) were transplanted into nude mice to establish hepatoma xenografts in nude mice. At 2 weeks after transplantation, the tumor was injected with telomerase inhibitor hTERT-5’RZ to treat transplanted hepatocellular carcinoma in nude mice. The injection time point was 9HALO or 21HALO for 2 weeks. Results The tumor inhibition rate (65%) and telomerase inhibition rate (90%) in 21HALO treatment group were higher than those in 9HALO treatment group (48%) and telomerase inhibition rate (70%), the difference was statistically significant significance. Conclusion The injection of telomerase-targeting ribozyme in tumor DNA synthesis period can better inhibit the growth of hepatocellular carcinoma and has a better therapeutic effect.